Norovirus Genogroup II Genotype 4 Virus-Like Particle (NoV GII.4 VLP)

Norovirus Genogroup II Genotype 4 (GII.4) Virus-Like Particles (VLPs) are non-infectious, recombinant protein complexes that mimic the icosahedral structure of the native norovirus capsid. Composed primarily of the major capsid protein VP1, these particles serve as a critical target for prophylactic vaccine development because GII.4 is the predominant genotype responsible for the majority of human norovirus outbreaks and global pandemics of acute gastroenteritis. Although VLPs lack the viral genome and cannot replicate, they retain the essential antigenic epitopes and receptor-binding domains needed to interact with human histo-blood group antigens (HBGAs), which are the primary receptors facilitating viral entry into the intestinal mucosa. In the context of drug development, GII.4 VLPs are utilized as the immunogenic component in clinical candidates such as HIL-214 (formerly TAK-214) to elicit robust systemic and mucosal neutralizing antibodies. These antibodies function by blocking the interaction between the viral capsid and host cell receptors, effectively preventing the virus from infecting enterocytes. A significant therapeutic challenge associated with this target is the rapid antigenic evolution and drift of GII.4 variants, which requires the development of broadly reactive or consensus VLPs to maintain efficacy against emerging epidemic strains.

Other names

Norovirus GII.4 capsid particleRecombinant GII.4 VP1 virus-like particleGII.4 NoV VLPNorovirus Genogroup II Genotype 4 capsidNoV GII.4 recombinant protein

Vaccine-mediated induction of neutralizing antibodies that competitively inhibit the binding of the viral VP1 capsid protein to host histo-blood group antigens (HBGAs), thereby preventing viral attachment and entry into intestinal epithelial cells.